CN103285301B - Method for preparing umbilicus dressing agent for treating stress incontinence - Google Patents
Method for preparing umbilicus dressing agent for treating stress incontinence Download PDFInfo
- Publication number
- CN103285301B CN103285301B CN201310270289.4A CN201310270289A CN103285301B CN 103285301 B CN103285301 B CN 103285301B CN 201310270289 A CN201310270289 A CN 201310270289A CN 103285301 B CN103285301 B CN 103285301B
- Authority
- CN
- China
- Prior art keywords
- parts
- stress incontinence
- filtrate
- dry extract
- reduced pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010066218 Stress Urinary Incontinence Diseases 0.000 title claims abstract description 21
- 208000022170 stress incontinence Diseases 0.000 title claims abstract description 20
- 210000001113 umbilicus Anatomy 0.000 title abstract description 12
- 238000000034 method Methods 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 31
- 241001604597 Pyrestini Species 0.000 claims abstract description 21
- 239000000706 filtrate Substances 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 241001506940 Alpinia japonica Species 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 18
- 241000242759 Actiniaria Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000010271 massa medicata fermentata Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 241001083548 Anemone Species 0.000 abstract description 3
- 244000144730 Amygdalus persica Species 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000218671 Ephedra Species 0.000 abstract 1
- 240000005067 Jasminum grandiflorum Species 0.000 abstract 1
- 235000004412 Jasminum grandiflorum Nutrition 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000218206 Ranunculus Species 0.000 abstract 1
- 241000765991 Trikeraia hookeri Species 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 210000003708 urethra Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 206010003694 Atrophy Diseases 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010046543 Urinary incontinence Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000167696 Prenanthes Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 208000013823 pelvic organ prolapse Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 241000218670 Ephedraceae Species 0.000 description 1
- 244000070010 Erythrina variegata Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000172774 Ranunculus ternatus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002163 alpha 1-adrenoceptor agonist Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000000475 female stress incontinence Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Abstract
The invention discloses a method for preparing an umbilicus dressing agent for treating stress incontinence, and aims to solve the problem about the medicament treatment of the stress incontinence. The method is characterized by comprising the following steps of: (1) distilling cortex erythrinae course powder, ternate buttercup root course powder and ephedra root course powder under a reduced pressure to extract volatile oil; (2) decocting kite gallbladder under a reduced pressure to obtain filtrate; (3) decocting trikeraia hookeri, alpinia japonica, jasminum grandiflorum, dark malt, baked medicated leaven, spina gleditsiae, peach tree glue, irkutsk anemone rhizome and medicaments residues obtained in the step (1) to obtain filtrate for later use; (4) merging the filtrate obtained in the step (2) and the filtrate obtained in the step (3), concentrating the merged filtrate under a reduced pressure to obtain dry extract, and smashing the dry extract to obtain dry extract powder; and (5) spraying the volatile oil obtained in the step (1) to the dry extract powder obtained in the step 4, uniformly mixing the volatile oil and the dry extract powder, screening the mixture by a sieve of 100 meshes, and subpackaging to obtain the umbilicus dressing agent. Clinical experiments prove that the medicament for treating the stress incontinence has the characteristics of good treating effect and high safety, and is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind ofly treat the preparation method that stress incontinence applies umbilicus agent.
Background technology
Stress incontinence (Stress Urinary Incontinence, SUI) refers to that the abdominal pressure such as sneeze or cough occurs when increasing that involuntary urine is from external orifice of urethra seepage.The abdominal pressures such as Symptoms is cough, sneeze, laugh independently do not overflow when increasing and urinate.When sign is abdominal pressure increase, can observe that urine does not independently flow out from urethra.When urodynamics test shows as filling cystometry, in abdominal pressure increase without occurring nonvoluntary leakage of urine when detrusor contractions.With age, female incontinence prevalence increases gradually, and the age occurred frequently is 45 ~ 55 years old.The dependency of age and urinary incontinence may with advancing age and the relaxed pelvic floor occurred, estrogen decrease and sphincter of urethra degeneration etc. are relevant.
Treatment main principle is treatment protopathy, improves symptom, protects from infection, renal function protecting.Drug therapy is mainly selectivity α 1-adrenoceptor agonists, can stimulate urethral smooth muscle α 1 receptor, and stimulates somatic movement neuron, increases urethral resistance.Side effect is hypertension, cardiopalmus, headache, acra feel cold, and severe patient can show effect apoplexy.
Because stress incontinence and pelvic organ prolapse are closely related, the two is normal with existing, so previously the traditional Chinese medical science thinks that this disease is deficiency syndrome, the setting about for the treatment of is a little to tonify Qi of the kidney, the representative prescription commonly used as large complement decoct, Gu Yin decocts.But inventor's clinical research finds that estrogenic minimizing, atrophy of external genitalia, denervation, blood supply minimizing and cicatrization etc. all can cause mucous membrane of urethra atrophy, gauffer reduces, thus urethra is followed the string, suitable closedown swaging can not be provided to become urinary incontinence.Also namely this disease also has mucous membrane of urethra solid pathological product to occur on deficiency syndrome basis, so should fully take into account mucous membrane of urethra to lose foster atrophy, these key pathological links of connective tissue arrangement disorder fibrosis.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the little treatment stress incontinence of side effect applies umbilicus agent.
The technical scheme that the present invention solves its technical problem is: one is treated stress incontinence and applied umbilicus agent, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Flos jasmini 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts.
Chinese medicine of the present invention can be prepared from by following method:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
The pressure of the distilling under reduced pressure in above-mentioned steps (1) is 0.1Mpa.
The pressure that decompression in above-mentioned steps (2) decocts is 0.4Mpa.
The pressure of the concentrating under reduced pressure in above-mentioned steps (4) is 0.4Mpa.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.Merit can heat-clearing and toxic substances removing; Dissipating blood stasis stops blooding.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.Merit can tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; Wind syndrome of head is had a headache; Weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq., is Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are pungent, warm.Return lung, spleen, Liver Channel.Merit can dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Flos jasmini is Oleaceae plants Flos jasmini Jasminu, the dry flower of grandiflorum L..Property mildly bitter flavor; Property is put down.Return Liver Channel.Merit can soothing liver-QI for relieving depression, promoting the circulation of QI to relieve pain.
Radix Ranunculi Ternati is the dried root of ranunculaceae plant Seynuns Kugelann Ranunculus ternatus Thunb..Nature and flavor sweet, acrid, warm.Return liver, lung meridian.Merit can eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven of fermentation, fry to burnt brown according to frying method.Nature and flavor sweet, acrid, warm.Enter spleen, stomach warp.Merit can invigorating the spleen and regulating the stomach, helps digestion in adjusting.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, flat.GUIXIN, lung meridian.Merit can hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are pungent, temperature.Return liver, stomach warp.Merit can be subsided a swelling poison holding, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant Fructus Persicae Prunus persica (L.) Batsch, the resin that trunk flows out.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae, is Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are pungent, temperature.Merit can causing resuscitation with aromatic drugs, reduces phlegm, calms the nerves.
Composition principle: stress incontinence and pelvic organ prolapse are closely related, the two is normal with existing, so previously the traditional Chinese medical science thinks that this disease is deficiency syndrome, the setting about for the treatment of is a little to tonify Qi of the kidney, the representative prescription commonly used as large complement decoct, Gu Yin decocts.But inventor's clinical research finds that estrogenic minimizing, atrophy of external genitalia, denervation, blood supply minimizing and cicatrization etc. all can cause mucous membrane of urethra atrophy, gauffer reduces, thus urethra is followed the string, suitable closedown swaging can not be provided to become urinary incontinence.Also namely this disease also has mucous membrane of urethra solid pathological product to occur on deficiency syndrome basis, so should fully take into account mucous membrane of urethra to lose foster atrophy, these key pathological links of connective tissue arrangement disorder fibrosis.
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using medicine of tonifying Qi of the kidney in a large number: get Cortex erythrinae in side, go back bobbin for monarch, the Cortex erythrinae dosage recorded in " China is herbal " is: " for oral administration: to decoct soup, 6-12g "; Inventor to test in proof heavy dose of Cortex erythrinae (10 ~ 30g) and can recover by specific promotion urethral wall mucosa, and goes back bobbin and have similar plants estrogen action, but this act as two-ways regulation, can not produce the low differentiation of estrogen excessive stimulation reproductive system cell;
2, characteristic of the present invention is also balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbid ", but gerontal patient's resembling often with deficiency of YIN-blood, and now use Cortex erythrinae, then have and fear its hematozemia and cause yin asthenia generating intrinsic heat to occur; Therefore add Herba Chlorophyti Laxi and go back bobbin, also bobbin merit can train base by tonify deficiency, and can prevent Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize on the one hand it coldly to prevent heated, its merit can dissipating blood stasis hemostasis on the other hand, has out entire merit in blood system, prevent Cortex erythrinae to wander away dynamic blood, also can not affect Cortex erythrinae works orderly effect simultaneously; 2. in we, the use of Rhizoma Anemones Altaicae is: a causing resuscitation with aromatic drugs and benefaction, two Yin Yang balancings, and to balance the bitter cold of our invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae is activated yang and do not consume the moon in addition, is suitable for old people and uses; In prescription of the present invention, the application characteristic of Rhizoma Anemones Altaicae is: measure larger (consumption in " Chinese Pharmacopoeia " is 1.5-6g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, supplementary drug thing is fewer but better: get Alpinia japonica (Thunb.) Miq. assistant in side and help Herba Chlorophyti Laxi, it act as giving treatment in accordance with the tendency of pathological change, regulating air activity; Radix Ranunculi Ternati and Herba Chlorophyti Laxi are arranged in pairs or groups removing toxic substances, eliminating stagnation effect, for these pathological products of connective tissue arrangement disorder fibrosis; Inventor's clinical research shows: Flos jasmini can alleviate bladder irritation effectively; Gumshiraz is invigorated blood circulation, and contributes to drag residence in local, penetration enhancement;
4, inventor's clinical research finds, solid protection gastric qi contributes to the process control of stress incontinence drug disease and recovery, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite;
5, Spina Gleditsiae is supplementary drug thing, record in " China book on Chinese herbal medicine " consumption be: " for oral administration: to decoct soup, 6 ~ 12g ", the present inventor's experimental study finds, gets low dose of Spina Gleditsiae decocting liquid and can improve in vitro mucous membrane of urethra cytoactive;
6, the homogeneous medicine multiple-effect of institute's thing of getting it filled in side, contributes to reducing medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, and each raw material dosage is for all to have good curative effect in following weight parts scope.
8, the fruit that bobbin is orchid Rhizoma Gastrodiae is gone back, compared with Rhizoma Gastrodiae, going back the Esterified Enzyme isozyme (esterase isoenzyme) that bobbin contains, may be that it plays the key of phytoestrogen effect, and inventor's experiment draws, it is higher that decompression goes back bobbin Esterified Enzyme isozyme content after decocting.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Flos jasmini 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: by Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Flos jasmini, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, the decoction of Rhizoma Anemones Altaicae mixing and water adding, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, crude drug weight proportion: Cortex erythrinae 10 parts, Herba Chlorophyti Laxi 6 parts, go back 3 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 parts, Flos jasmini 3 parts, Radix Ranunculi Ternati 6 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Massa Medicata Fermentata (parched to brown) 6 parts, Radix Ephedrae 6 parts, Spina Gleditsiae 1 part, gumshiraz 3 parts, Rhizoma Anemones Altaicae 10 parts.
Embodiment 3, crude drug weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Flos jasmini 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Embodiment 4, crude drug weight proportion: Cortex erythrinae 30 parts, Herba Chlorophyti Laxi 12 parts, go back 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 12 parts, Flos jasmini 10 parts, Radix Ranunculi Ternati 12 parts, Fructus Hordei Germinatus (parched to brown) 12 parts, Massa Medicata Fermentata (parched to brown) 12 parts, Radix Ephedrae 12 parts, Spina Gleditsiae 5 parts, gumshiraz 10 parts, Rhizoma Anemones Altaicae 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
In prioritization scheme, the pressure of the distilling under reduced pressure in described step (1) is 0.1Mpa; The pressure that decompression in described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in described step (4) is 0.4Mpa.
The efficient combination of said medicine, coordinates mutually, effectively reach the object for the treatment of stress incontinence medicine, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case selection: in January, 2011 ~ 2013 are diagnosed as stress incontinence female patient 100 example year June, and eliminating excreting excrement system infects and kidney disease, previously without operation on pelvis history and neuromuscular pathological changes.Entering to organize case age distribution is 44 ~ 72 years old, and the course of disease 2 months ~ 5 years, is multipara.
1.1.2 the diagnostic criteria of stress incontinence: time 1. firmly, autonomous leakage of urine appears in while changing position (cough, laugh, remove weight); 2. Pad test: namely allow patient bring menopad, jog after great quantity of water drinking, stair climbing, lift the activities such as weight, checks after 30min, 60min that menopad finds that leakage of urine and moist person are for positive.Any one in above-mentioned two is positive, and diagnosable is stress incontinence.
1.1.3 divide into groups: be divided into soak group 50 example and deposited umbilicus group 50 example.Compare in age, the state of an illness, the course of disease before two groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: soak group with gained decoct umbilical part soak in the embodiment of the present invention 1,3 times/d.Applying umbilicus group adjusts rear umbilical part to dress with gained powder vinegar in the embodiment of the present invention 3,1 time/d.It within 4 weeks, is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after medication, and carry out general questionnaire and international urinary incontinence Advisory Board urinary incontinence questionnaire table abridged table (ICIQ-SF) investigation scoring, evaluate its situation of urinating.
1.2.3 criterion of therapeutical effect: Pad test <1g is effective, 1 ~ 3g is effectively, invalid without being improved as before symptom and treatment after treatment.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.ICIQ-SF scoring adopts nonparametric statistics.Measurement data t checks, enumeration data χ
2inspection.
2 results.
Situation scoring of urinating before and after 2.1 liang of group treatments is compared: before treatment, soak group and deposited umbilicus group situation of urinating are respectively: 7.23 ± 2.24,7.62 ± 1.98; Treating two groups of scorings after 4 weeks is: 4.45 ± 1.22,4.02 ± 1.82.Before and after two groups of treatments, difference all has statistical significance (P<0.05).
2.2 clinical efficacies: medication is after 4 weeks, and the obvious effective rate of soak group, effective percentage, inefficiency are respectively 54.00%, 34.00%, 12.00%, total effective rate is 88.00%.The obvious effective rate of deposited umbilicus group, effective percentage, inefficiency are respectively 48.00%, 36.00%, 16.00%, and total effective rate is 84.00%.
2.3 adverse reaction rates: two groups of patients all do not occur obvious adverse reaction.
3. conclusion.
This result of study shows, and soak group of the present invention and deposited umbilicus group treatment stress incontinence total effective rate are respectively 88.00% and 84.00%.Have the advantage that untoward reaction is comparatively light, safety is higher.
Claims (4)
1. treat the preparation method of stress incontinence drug powder for one kind, it is characterized in that, crude drug is: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Flos jasmini 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts, and its preparation method is made up of following steps:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Flos jasmini, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
2. a kind of preparation method for the treatment of stress incontinence drug powder according to claim 1, is characterized in that: the pressure of the distilling under reduced pressure in described step (1) is 0.1Mpa.
3. a kind of preparation method for the treatment of stress incontinence drug powder according to claim 1, is characterized in that: the pressure that the decompression in described step (2) decocts is 0.4Mpa.
4. a kind of preparation method for the treatment of stress incontinence drug powder according to claim 1, is characterized in that: the pressure of the concentrating under reduced pressure in described step (4) is 0.4Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310270289.4A CN103285301B (en) | 2013-07-01 | 2013-07-01 | Method for preparing umbilicus dressing agent for treating stress incontinence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310270289.4A CN103285301B (en) | 2013-07-01 | 2013-07-01 | Method for preparing umbilicus dressing agent for treating stress incontinence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103285301A CN103285301A (en) | 2013-09-11 |
| CN103285301B true CN103285301B (en) | 2015-04-15 |
Family
ID=49087190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310270289.4A Expired - Fee Related CN103285301B (en) | 2013-07-01 | 2013-07-01 | Method for preparing umbilicus dressing agent for treating stress incontinence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285301B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804169A (en) * | 2010-05-28 | 2010-08-18 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating urinary incontinence and preparation method thereof |
-
2013
- 2013-07-01 CN CN201310270289.4A patent/CN103285301B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804169A (en) * | 2010-05-28 | 2010-08-18 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating urinary incontinence and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 尿失禁的辨证施治;陈美娟;《哈尔滨医药》;20081231;第28卷(第5期);第45-46页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103285301A (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103877247A (en) | Medicine for treating bedsore and preparation method thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301372B (en) | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN103285301B (en) | Method for preparing umbilicus dressing agent for treating stress incontinence | |
| CN106110218B (en) | A kind of anti-cancer pain pain relieving plaster and preparation method thereof | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103301371B (en) | Preparation method of umbilicus dressing agent for treating primary enuresis | |
| CN103301375B (en) | Preparation method of umbilical sticking agent for treating nocturia of children | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103301378B (en) | Pharmaceutical composition for treating nocturia of children | |
| CN105998519A (en) | Oral medicine for treating frequent micturition due to pelvic inflammatory disease | |
| CN106166206A (en) | A kind of gynecological inflammation causes the rehabilitation medicine preparation method of frequent micturition | |
| CN104940524A (en) | Medicine for treating leucoderma and preparation method thereof | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: XIN JIANWEI Free format text: FORMER OWNER: XIAO LI Effective date: 20150316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xin Jianwei Inventor after: Liu Yurong Inventor after: Sun Tao Inventor after: Zhuang Lanlan Inventor before: Xiao Li Inventor before: Zhuang Lanlan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XIAO LI ZHUANG LANLAN TO: XIN JIANWEI LIU YURONG SUN TAO ZHUANG LANLAN Free format text: CORRECT: ADDRESS; FROM: 276800 RIZHAO, SHANDONG PROVINCE TO: 261500 WEIFANG, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150316 Address after: 261500 Gaomi City people's Hospital of Shandong Province, Gaomi City, Weifang Province, 77 Town Street (West), Shandong Applicant after: Xin Jianwei Address before: 276800 Juxian People's Hospital of Shandong, Rizhao City Province, China Applicant before: Xiao Li |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150415 Termination date: 20160701 |